ENA-001 (formerly GAL-021)[1] is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel,[2] although secondary mechanisms may also be involved.

[3] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care,[4] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs.

[5][6][7] This drug article relating to the respiratory system is a stub.

You can help Wikipedia by expanding it.